| Bioactivity | Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis[1][2][3][4]. |
| Target | Prostaglandin. |
| Invitro | Benorylate (Salipran) is an esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin[1].Benorylate (Salipran) causes a large decrease in the liver’s conversion rate of lactate into glucose, an important component of glucose homeostasis. Benorylate (Salipran) also impairs the urea synthesis rate from ammonia, another important function of the liver[2]. |
| In Vivo | Benorylate (Salipran) is probably absorbed as the intact molecule which accounts for its good gastric tolerance[3]. Benorylate (Salipran) could inhibit PG synthesis in laboratory animals and in human tissue[4]. |
| Name | Benorilate |
| CAS | 5003-48-5 |
| Formula | C17H15NO5 |
| Molar Mass | 313.30 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3(5826):545-7. [2]. Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15(8-9):743-9. [3]. Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8. [4]. A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105. |